Results 151 to 160 of about 778,750 (285)

Maternal Obesity Programs Glucose Intolerance in Pregnant Female Offspring. [PDF]

Diabetes
Qiao L, Lu C, Saget S, Shao J.
europepmc   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Gestational Glucose Intolerance and Risk of Obesity in Childhood and Adolescence. [PDF]

J Clin Endocrinol Metab
Maya J, Schulte CCM, Hsu S, James K, Thaweethai T, Pant D, Hivert MF, Powe CE.   +7 more
europepmc   +1 more source

Systematic Comparison of High‐Fat Diet– and Streptozotocin‐Induced Prediabetic Obese C57BL/6J Mouse Models: A Sex‐Based Protocol Optimization Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Animal models of prediabetes (Pre‐DM) are essential for studying metabolic disease and testing therapies, yet high‐fat diet (HFD) and HFD‐plus‐streptozotocin (STZ) protocols vary in feeding duration, STZ dose, and diagnostic criteria and rarely account for sex.
Min Xu, Chao Ke, Yangkun Liu, Wenying Shi, Yang Cao, Zhengyu Li, Yi Xiao, Wei Zhang   +7 more
wiley   +1 more source

Liraglutide and Βeta‐Cell Function in Young Adults With Long‐Standing Type 1 Diabetes and Residual C‐Peptide: A Blinded, Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effect of liraglutide on residual beta‐cell function in adults with long‐standing type 1 diabetes (T1D) and detectable C‐peptide. Materials and Methods In this randomized, blinded, placebo‐controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C‐peptide were assigned to liraglutide or placebo for 52 
José Caballero‐Corbalán, Per Lundkvist, Daniel Espes, Per‐Ola Carlsson   +3 more
wiley   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Editorial: Recent advances in secondary diabetes and glucose intolerance. [PDF]

Front Endocrinol (Lausanne)
Abe I, Fukuoka H, Igata M, Kodagoda Gamage S.   +3 more
europepmc   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver disease. [PDF]

NPJ Metab Health Dis
Zeibak M, Karbian N, Riahi Y, Baraghithy S, Ahmad L, Tabib A, Abromovitz I, Agranovitz B, Benyamini H, Gottlieb E, Tam J, Dor Y, Leibowitz G, Mevorach D.   +13 more
europepmc   +1 more source

Evaluating Whole Fruit Feijoa Powder for Type 2 Diabetes Risk Prevention: A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Low energy diets (LEDs) are effective for body weight (BW) loss and improvement of type 2 diabetes (T2D) risk biomarkers. Emerging evidence suggests that whole fruit feijoa powder, rich in polyphenols and abscisic acid, may further support T2D prevention.
I. A. Mohamed, I. R. Sequeira‐Bisson, J. J. Lim, L. D. Plank, R. Murphy, S. D. Poppitt, J. L. Miles‐Chan   +6 more
wiley   +1 more source